[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338792-105":59,"doc-detail-338792-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","fgl2-promotes-tumour-growth-and-attenuates-infiltration-of-activated-immune-cells-in-melanoma-and-ovarian-cancer-models","FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models","","Tumour escape is driven by immunosuppressive cells in the tumour microenvironment (TME), including regulatory T cells (Tregs), which limit effective immunotherapy. Soluble fibrinogen-like protein 2 (sFGL2) is described as a Treg effector that inhibits immune cell functions through FcγRIIB and FcγRIII, affecting antigen presentation by downregulating CD86 and constraining T cell activation. Using Fgl2 knockout mice, the study tests FGL2 roles in melanoma and epithelial ovarian cancer models, finding that FGL2 absence yields a more activated TME, enhanced DCs, T cells, and natural killer cell activation, improved melanoma survival, and synergistic benefits with oncolytic virus in ovarian cancer.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/fgl2-promotes-tumour-growth-and-attenuates-infiltration-of-activated-immune-cells-in-melanoma-and-ovarian-cancer-models/338792/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/fgl2-promotes-tumour-growth-and-attenuates-infiltration-of-activated-immune-cells-in-melanoma-and-ovarian-cancer-models/338792.png","ImageObject",300,407,{"name":92,"@type":93},"Jiven","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"How does sFGL2 suppress immune responses in the tumour microenvironment?","Question",{"text":112,"@type":113},"sFGL2 acts through FcγRIIB and FcγRIII to promote immunosuppression. It contributes to reduced antigen-presenting capacity, including downregulation of CD86, and thereby limits T cell activation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which immune cell populations are affected when FGL2 is absent?",{"text":117,"@type":113},"Loss of FGL2 results in a more activated TME, including activated dendritic cells and T cells. It also increases activation of natural killer cells in the TME.",{"name":119,"@type":110,"acceptedAnswer":120},"What are the reported effects of targeting FGL2 on survival in cancer models?",{"text":121,"@type":113},"In the B16F10 melanoma model, absence of FGL2 prolongs survival. In the ID8-p53−/−Brca2−/− ovarian cancer model, FGL2 absence synergizes with oncolytic virus to prolong survival.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338792,1790187129,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},1099513958607,"https://ap-avatar.wpscdn.com/avatar/100002390cf8733938c?x-image-process=image/resize,m_fixed,w_180,h_180&k=1778829742770036399","[www. nature.com/scientificreports](www. nature.com/scientificreports)  \nOPEN  \nFGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models  \nKristianne J. C. Galpin1,2, Galaxia M. Rodriguez1,2, Vincent Maranda1,2, David P. Cook 1,2, Elizabeth Macdonald1,2, Humaira Murshed1,2, Shan Zhao1,2, Curtis W. McCloskey1,2, Andrzej Chruscinski3, Gary A. Levy 3, Michele Ardolino1,4 & Barbara C. Vanderhyden1,2*  \nThe tumour microenvironment is infiltrated by immunosuppressive cells, such as regulatory T  \ncells (Tregs), which contribute to tumour escape and impede immunotherapy outcomes. Soluble fibrinogen-like protein 2 (sFGL2), aTreg effector protein, inhibits immune cell populations, via receptors FcγRIIB and FcγRIII, leading to downregulation of CD86 in antigen presenting cells and limiting T cell activation. Increased FGL2 expression is associated with tumour progression and poor survival in several different cancers, such as glioblastoma multiforme, lung, renal, liver, colorectal, and prostate cancer. Querying scRNA-seq human cancer data shows FGL2 is produced by cells in the tumour microenvironment (TME), particularly monocytes and macrophages as well asT cells and dendritic cells (DCs), while cancer cells have minimal expression of FGL2. We studied the role of FGL2 exclusively produced by cells intheTME, by leveraging Fgl2 knockout mice. We tested two murine models of cancer in which the role of FGL2 has not been previously studied: epithelial ovarian cancer and melanoma. We show that absence of FGL2 leads to a more activated TME, including activated DCs (CD86+, CD40+) and T cells (CD25+, TIGIT+), as well as demonstrating for the first time that the absence of FGL2 leads to more activated natural killer cells (DNAM-1+, NKG2D+) intheTME. Furthermore, the absence of FGL2 leads to prolonged survival in the B16F10 melanoma model, while the absence of FGL2 synergizes with oncolytic virus to prolong survival in the ID8-p53−/−Brca2−/− ovarian cancer model. In conclusion, targeting FGL2 is a promising cancer treatment strategy alone and in combination immunotherapies.  \nFibrinogen-like protein 2 (FGL2) is a multi-functional protein expressed in macrophages1,2, T cells (notably Tregs and TIGIT+ Tregs)3–6, natural killer (NK) cells7, dendritic cells (DCs)8, myeloid derived suppressor cells (MDSCs)9, endothelial cells 10, 11, and cancer associated fibroblasts (CAFs)12. FGL2 can be found in either a secreted form (sFGL2)3,5 with immunosuppressive properties, or a membrane-bound form (mFGL2)13 with prothrombinase activity, with both forms derived from the same transcript. sFGL2 is involved in numerous immunoregulatory processes as shown in viral14, 15 and parasitic infections16, 17, promoting allo/xenograft tolerance3, 18, 19, and restricting progression of autoimmune diseases such as glomerulonephritis5, hepatitis20, myocarditis21, and arthritis22. It also has protective roles in inflammatory conditions such as sepsis9 and colitis23,24.  \nsFGL2 acts directly on immune cell populations via its receptors FcγRIIB and FcγRIII5, to promote immunosuppression3,20. sFGL2 leads to B cell apoptosis5, or downregulation of MHC-II and co-stimulatory molecules (CD86, CD83, CD80, and CD40) on DCs and macrophages3,5,25. CD25+ FOXP3+ Tregs have high expression of FGL2, suggesting that FGL2 is a Treg effector that suppresses effector T cell proliferation3,5,26.  \n1Cancer Therapeutics Program, Ottawa Hospital Research Institute, 501 Smyth Road, Ottawa, ON K1H 8L6, Canada. 2Department of Cellular and Molecular Medicine, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada. 3Multi-Organ Transplant Program, Toronto General Hospital, University Health Network, University of Toronto, Toronto, ON, Canada. 4Department of Biochemistry, Microbiology and Immunology, University of Ottawa, 451 Smyth Road, Ottawa, ON K1H 8M5, Canada.* email: [bvanderhyden@ohri.ca](bvanderhyden@ohri.ca)  \n[www. nature.co","cbCaiev9WRblDnhX","https://ap.wps.com/l/cbCaiev9WRblDnhX","pdf",2468770,15,"English","# FGL2 and immunosuppression in the tumour microenvironment\n## Mechanistic background of sFGL2 (receptors and immune effects)\n## Expression patterns of FGL2 in tumour microenvironment cells\n## Experimental approach using Fgl2 knockout models\n## Outcomes in melanoma and ovarian cancer models","[{\"question\":\"How does sFGL2 suppress immune responses in the tumour microenvironment?\",\"answer\":\"sFGL2 acts through FcγRIIB and FcγRIII to promote immunosuppression. It contributes to reduced antigen-presenting capacity, including downregulation of CD86, and thereby limits T cell activation.\"},{\"question\":\"Which immune cell populations are affected when FGL2 is absent?\",\"answer\":\"Loss of FGL2 results in a more activated TME, including activated dendritic cells and T cells. It also increases activation of natural killer cells in the TME.\"},{\"question\":\"What are the reported effects of targeting FGL2 on survival in cancer models?\",\"answer\":\"In the B16F10 melanoma model, absence of FGL2 prolongs survival. In the ID8-p53−/−Brca2−/− ovarian cancer model, FGL2 absence synergizes with oncolytic virus to prolong survival.\"}]","FGL2 promotes tumour growth and attenuates infiltration of activated immune cells in melanoma and ovarian cancer models | PDF",1790025693,38,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/959336f71f2f3c993e98e4c294adfe9c.webp",983,1291,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bf370d92e351fa4781326be37a3de206.webp",982,1290,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/26be39597e2683acabbc8c87555cd31d.webp",981,1289,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a893b1ce919ed0aaa791e6d41ac4dfd8.webp",980,1287]